Safinamide
CAS No. 133865-89-1
Safinamide ( EMD-1195686 | FCE-26743 )
产品货号. M11361 CAS No. 133865-89-1
一种有效的选择性 MAO-B 抑制剂,IC50 为 98 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥316 | 有现货 |
|
| 10MG | ¥437 | 有现货 |
|
| 25MG | ¥745 | 有现货 |
|
| 50MG | ¥1110 | 有现货 |
|
| 100MG | ¥1596 | 有现货 |
|
| 500MG | ¥4155 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Safinamide
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种有效的选择性 MAO-B 抑制剂,IC50 为 98 nM。
-
产品描述A potent and selective inhibitor of MAO-B with IC50 of 98 nM; displays >5,000-fold selectivity over MAO-A; also inhibits glutamate release and dopamine reuptake, inhibits voltage-dependent Na+ and Ca2+ channels; is used for treatment ofParkinson's disease.Parkinson's Disease Approved.
-
体外实验Safinamide (1–300?μM) reduces the amplitude of the peak sodium currents in a concentration-dependent manner.?When currents are stimulated to a?Vtest?of +10 mV from a?Vh?of -110 mV, the IC50?value was 262?μM. When the holding potential is depolarized to -53 mV, the inhibitory effect of safinamide with a lower IC50?value (8?μM) in rat cortical neurons.
-
体内实验Safinamide (intraperitoneal?injection; 90 mg/kg; once daily; 14 days) treatment prior to MCAO significantly ameliorates MCAO-caused cerebral infarction volume, neurological deficit, disruption of the brain-blood barrier (BBB), and impairs expression of tight junction protein occludin and ZO-1 in mice.Safinamide (intraperitoneal?injection; 5 mg/kg, 15 mg/kg and 30 mg/kg) dose dependently inhibits the veratridine-induced GABA release and Glu release in vivo. At the dose 30 mg/kg, ?Safinamide prevents the effect of veratridine both on Glu (treatment?F1,8=1.31; time×treatment interaction?F8,64=2.4) and GABA (treatment?F1,8=4.04; time?F8,64=3.76, time×treatment interaction?F8,64?= 2.83) release.Safinamide causes a slight, albeit not significant, reduction of veratridine-stimulated Glu release at 0.5 mg/kg and full inhibition at 5 and 15 mg/kg in rat. Animal Model:Focal cerebral ischemia C57/BL6 male mouse ModelDosage:90 mg/kg Administration:Intraperitoneal?injection; once daily; 14 days Result:Significantly decreased infarction volume in brain areas.
-
同义词EMD-1195686 | FCE-26743
-
通路Metabolic Enzyme/Protease
-
靶点MAO
-
受体MAO
-
研究领域Neurological Disease
-
适应症Parkinson Disease
化学信息
-
CAS Number133865-89-1
-
分子量302.3434
-
分子式C17H19FN2O2
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F
-
化学全称Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Leonetti F, et al. J Med Chem. 2007 Oct 4;50(20):4909-16.
2. Strolin Benedetti MS, et al. J Pharm Pharmacol. 1994 Oct;46(10):814-9.
3. Caccia C, et al. Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23.
产品手册
021-51111890
购物车()
sales@molnova.cn

